FENTANYL
Polyps
Mount Carmel Health SystemSmall moleculePhase 4 / ApprovedDormant
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 53/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Polyps cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PROPOFOL Mount Carmel Health System | Phase 4 | BB |
MIDAZOLAM Mount Carmel Health System | Phase 4 | BB |
MARBLE DUST Dartmouth-Hitchcock Medical Center | Phase 2/3 | B |
Acetylsalicylic Acid Dartmouth-Hitchcock Medical Center | Phase 2/3 | B |
Folate Dartmouth-Hitchcock Medical Center | Phase 2/3 | B |
Same molecule, other indications
FENTANYL is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →